PMID- 35931198
OWN - NLM
STAT- MEDLINE
DCOM- 20221012
LR  - 20221014
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 307
DP  - 2022 Oct 15
TI  - Sinapic acid ameliorates airway inflammation in murine ovalbumin-induced allergic 
      asthma by reducing Th2 cytokine production.
PG  - 120858
LID - S0024-3205(22)00558-6 [pii]
LID - 10.1016/j.lfs.2022.120858 [doi]
AB  - OBJECTIVE: Asthma is a chronic inflammatory airway disease associated with the 
      airway narrowing and obstruction. Sinapic acid (SA), a hydroxycinnamic acid, 
      possesses various pharmacological properties including antioxidant and 
      anti-inflammatory activity. This research evaluated effects of different doses of 
      SA on murine model of ovalbumin (OVA)-induced allergic asthma. MATERIALS AND 
      METHODS: Allergic asthma induced by sensitizing mice on days 1 and 14 by 
      intraperitoneal injection of OVA. After initial sensitization, between days 21 
      and 23, mice were challenged for 30 min with an aerosol of 1 % (wt/vol) OVA. 
      Treatment with dexamethasone (3 mg/kg) or SA (25, 50 or 100 mg/kg) were done by 
      oral gavage on days 15-23. Inflammatory cells infiltration and interferon-gamma 
      (IFN-gamma), interlukin-4 (IL-4), IL-5 and IL-13 levels were evaluated in the 
      bronchoalveolar lavage fluid (BALF). Serum total and OVA-specific immunoglobulin 
      E (IgE) and lung tissue nitric oxide (NO) levels were measured. Histological 
      changes in lung tissue were examined by staining with hematoxylin and eosin (H&E) 
      for cell infiltration, periodic acid-Schiff (PAS) for mucus production and 
      Masson's trichrome for collagen deposition. RESULTS: Treatment with SA 
      significantly inhibited inflammatory cell infiltration, enhanced IFN-gamma level and 
      decreased IL-4, IL-5 and IL-13 levels in BALF. Serum total and OVA-specific IgE 
      levels and NO level in lung tissue were significantly reduced by SA. Histological 
      examination demonstrated that SA significantly attenuated inflammatory cell 
      infiltration and mucus-producing cells in the lung. CONCLUSION: These data 
      suggest that SA may be a new therapeutic potential to treat allergic asthma 
      through suppressing T-helper 2 immune responses.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Saeedavi, Morteza
AU  - Saeedavi M
AD  - Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, 
      Ahvaz, Iran.
FAU - Goudarzi, Mehdi
AU  - Goudarzi M
AD  - Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical 
      Sciences, Ahvaz, Iran.
FAU - Mehrzadi, Saeed
AU  - Mehrzadi S
AD  - Air Pollution Research Center, Iran University of Medical Sciences, Tehran, Iran.
FAU - Basir, Zahra
AU  - Basir Z
AD  - Department of Basic Sciences, Faculty of Veterinary Medicine, Shahid Chamran 
      University of Ahvaz, Ahvaz, Iran.
FAU - Hasanvand, Ali
AU  - Hasanvand A
AD  - Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, 
      Ahvaz, Iran.
FAU - Hosseinzadeh, Azam
AU  - Hosseinzadeh A
AD  - Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran. 
      Electronic address: hoseinzadeh.a@iums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20220803
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Coumaric Acids)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-13)
RN  - 0 (Interleukin-5)
RN  - 10450-60-9 (Periodic Acid)
RN  - 207137-56-2 (Interleukin-4)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 68A28V6010 (sinapinic acid)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9006-59-1 (Ovalbumin)
RN  - TDQ283MPCW (Eosine Yellowish-(YS))
RN  - YKM8PY2Z55 (Hematoxylin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antioxidants/therapeutic use
MH  - *Asthma/chemically induced/drug therapy
MH  - *Coumaric Acids/pharmacology/therapeutic use
MH  - Cytokines
MH  - Dexamethasone/therapeutic use
MH  - Disease Models, Animal
MH  - Eosine Yellowish-(YS)
MH  - Hematoxylin
MH  - Immunoglobulin E
MH  - Inflammation/drug therapy
MH  - Interferon-gamma
MH  - Interleukin-13
MH  - Interleukin-4
MH  - Interleukin-5
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nitric Oxide
MH  - Ovalbumin
MH  - Periodic Acid
MH  - Th2 Cells
OTO - NOTNLM
OT  - Allergic asthma
OT  - Inflammation
OT  - Ovalbumin
OT  - Pharmacology
OT  - Sinapic acid
OT  - T-helper 2 cells
COIS- Declaration of competing interest The authors declare that they have no conflict 
      of interest.
EDAT- 2022/08/06 06:00
MHDA- 2022/10/13 06:00
CRDT- 2022/08/05 19:24
PHST- 2022/05/24 00:00 [received]
PHST- 2022/07/24 00:00 [revised]
PHST- 2022/08/01 00:00 [accepted]
PHST- 2022/08/06 06:00 [pubmed]
PHST- 2022/10/13 06:00 [medline]
PHST- 2022/08/05 19:24 [entrez]
AID - S0024-3205(22)00558-6 [pii]
AID - 10.1016/j.lfs.2022.120858 [doi]
PST - ppublish
SO  - Life Sci. 2022 Oct 15;307:120858. doi: 10.1016/j.lfs.2022.120858. Epub 2022 Aug 
      3.